Haloperidol

證據等級: L5

預測適應症: 10 個

Haloperidol: From Antipsychotic Use to Manic Bipolar Affective Disorder

One-Sentence Summary

Haloperidol is a classic first-generation (typical) antipsychotic, globally recognized for treating schizophrenia, acute psychosis, and Tourette syndrome. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder (rank 10, score 99.83%), with 9 clinical trials and 20 publications providing robust support — notably including multiple completed Phase 3 RCTs where haloperidol served as an active comparator, yielding direct efficacy data.

⚠️ Note: Haloperidol is currently not registered in the Philippines. The top 9 TxGNN-ranked predictions (ranks 1–9) involve ultra-rare congenital/genetic disorders with no clinical evidence (L5), and are all recommended as Hold. This report focuses on rank 10 — manic bipolar affective disorder — which is the only prediction with actionable clinical evidence.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines. Globally approved for schizophrenia, acute psychosis, and Tourette syndrome
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.83%
Evidence Level	L1 (≥2 completed Phase 3 RCTs)
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

All TxGNN Predicted Indications Summary

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Congenital disorder of glycosylation with defective fucosylation	99.91%	L5	Hold
2	Retinal dystrophy with or without extraocular anomalies	99.91%	L5	Hold
3	Hydranencephaly	99.90%	L5	Hold
4	Myopia, X-linked	99.89%	L5	Hold
5	Charcot-Marie-Tooth disease, demyelinating, type 1G	99.89%	L5	Hold
6	Myopia 26, X-linked, female-limited	99.89%	L5	Hold
7	Syndromic myopia	99.88%	L5	Hold
8	Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis	99.88%	L5	Hold
9	Atypical glycine encephalopathy	99.87%	L5	Hold
10	Manic Bipolar Affective Disorder	99.83%	L1	Proceed with Guardrails

Ranks 1–9 involve ultra-rare genetic or congenital conditions with no mechanistic rationale for haloperidol’s D2 antagonism. Several predictions (ranks 4, 6, 7) may actually be contraindicated — D2 antagonism in the retina could worsen myopia progression. Rank 5 (CMT1G) raises safety concerns as antipsychotics may exacerbate peripheral neuropathy. Only rank 10 has a sound mechanistic basis and clinical evidence.

Why is This Prediction Reasonable?

Haloperidol is a butyrophenone-class dopamine D2 receptor antagonist. Its primary mechanism involves potent blockade of D2 receptors in the mesolimbic and mesocortical dopamine pathways. This dopaminergic antagonism directly addresses the hyperdopaminergic state that underlies the core pathophysiology of acute mania — including euphoria, grandiosity, psychomotor agitation, and psychotic features.

Manic episodes in bipolar I disorder are characterized by excessive dopaminergic activity in the mesolimbic system. Haloperidol’s high-affinity D2 blockade rapidly reduces this overactivation, making it mechanistically well-suited for acute mania management. In clinical practice, haloperidol has been used for treating acute mania for decades, often serving as the “gold standard” active comparator in clinical trials of newer atypical antipsychotics (risperidone, olanzapine, aripiprazole) for bipolar mania.

It is important to note that this prediction essentially validates a well-established clinical use rather than identifying a novel repurposing opportunity. Haloperidol is already approved for bipolar mania in numerous regulatory jurisdictions worldwide (e.g., FDA, EMA). The TxGNN model’s ability to independently recover this known indication serves as a positive control demonstrating the model’s validity for this drug. However, since haloperidol is not currently registered in the Philippines, there may be a regulatory pathway opportunity if local market need exists.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00253162	Phase 3	Completed	439	Risperidone vs Haloperidol vs Placebo in manic episodes of bipolar I disorder; haloperidol as active comparator over 12 weeks demonstrating sustained efficacy
NCT00253149	Phase 3	Completed	158	Risperidone vs Haloperidol as add-on to mood stabilizers for bipolar mania treatment
NCT00129220	Phase 3	Completed	224	Olanzapine vs Haloperidol vs Placebo in manic/mixed episodes of bipolar I disorder; head-to-head comparison design
NCT00097266	Phase 3	Completed	615	Aripiprazole monotherapy vs Haloperidol (active control) for acute mania over 12 weeks; largest trial in dataset
NCT00126009	Phase 2	Completed	120	Valproate-Amisulpride vs Valproate-Haloperidol (5–15 mg/day) combination therapy in manic episodes over 3 months
NCT04327843	Phase 3	Completed	22	Long-acting injectable antipsychotics combined with behavioral program for chronic psychotic disorders including bipolar disorder in Tanzania
NCT00767715	Phase 4	Terminated	11	Olanzapine vs conventional antipsychotics (including haloperidol) in acute mania in Sweden; terminated due to poor enrollment
NCT03541031	N/A	Unknown	120	Micronutrient supplementation as adjunctive treatment for bipolar disorder
NCT06049953	N/A	Recruiting	200	Observational study on developmental effects of antenatal antipsychotic exposure in pregnant individuals with severe mental illness

Summary: 4 completed Phase 3 RCTs directly include haloperidol as an active comparator arm, collectively enrolling over 1,400 patients. This exceeds the L1 threshold (≥2 completed Phase 3 RCTs) with strong confidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34642461	2022	Systematic Review / NMA	Molecular Psychiatry	Comprehensive network meta-analysis comparing pharmacological treatments for acute bipolar mania from all available RCTs; positions haloperidol among effective interventions
22134043	2012	RCT	Journal of Affective Disorders	Randomized double-blind trial of olanzapine vs haloperidol vs placebo in Japanese bipolar I patients with manic/mixed episodes; first Asian population-specific data
3312180	1987	RCT	J Clinical Psychiatry	Double-blind trial comparing clonazepam with haloperidol in acutely manic patients; demonstrated haloperidol’s established efficacy as benchmark
369472	1979	RCT	Archives of General Psychiatry	Controlled trial of lithium + haloperidol vs placebo + haloperidol in schizoaffective disorder; showed additive benefit of combination therapy
33460070	2020	Clinical Review	Acta Psychiatrica Scandinavica	Evidence-based review of mania treatment options; includes haloperidol as a recommended option among mood stabilizers and antipsychotics
22070611	2012	Review	CNS Neuroscience & Therapeutics	Reviews treatment of refractory bipolar disorder; recommends adding haloperidol to lithium/valproate partial responders
36789916	2023	Comparative Analysis	BMJ Mental Health	Comparison of antipsychotic dose equivalents between acute mania and schizophrenia; provides dosing guidance for haloperidol in mania
15147609	2004	HTA / Systematic Review	Health Technology Assessment	Systematic review and economic evaluation of treatments for bipolar mania; haloperidol included as comparator across multiple analyses
18344731	2008	Systematic Review	J Clinical Psychopharmacology	Systematic comparison of antipsychotic-induced EPS in bipolar disorder vs schizophrenia; important safety data for haloperidol use in mania
10343182	1999	Mechanism Study	Neuropsychobiology	Lithium and haloperidol differentially affect Gαs protein levels in bipolar patients; provides mechanistic insight into haloperidol’s action in bipolar disorder

Philippines Market Information

Haloperidol is not currently registered in the Philippines. No FDA Philippines authorizations were found.

Item	Status
Market Status	Not marketed
Total Registrations	0
Available Dosage Forms	None registered

Haloperidol is widely available globally and appears on the WHO Model List of Essential Medicines. Its absence from the Philippines market may represent a registration gap rather than a safety/efficacy concern.

Safety Considerations

Please refer to the package insert for safety information.

Detailed safety data (warnings, contraindications, drug interactions) were not available in the current evidence pack. Based on haloperidol’s well-established global safety profile, key considerations include:

Extrapyramidal Symptoms (EPS): Haloperidol has a high incidence of acute dystonia, akathisia, parkinsonism, and tardive dyskinesia — particularly relevant in bipolar patients who may require long-term maintenance
QTc Prolongation: Risk of Torsades de Pointes, especially with IV administration or at higher doses
Neuroleptic Malignant Syndrome (NMS): Rare but life-threatening; requires immediate discontinuation
Black Box Warning (US FDA): Increased mortality in elderly patients with dementia-related psychosis
Metabolic Effects: Lower metabolic risk compared to atypical antipsychotics, but monitoring still recommended

⚠️ Data Gap: Philippine-specific prescribing information, local package insert warnings, and DDI data require supplementation from FDA Philippines or the manufacturer.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Haloperidol’s efficacy in acute bipolar mania is supported by multiple completed Phase 3 RCTs (L1 evidence) and decades of global clinical experience. The D2 antagonism mechanism directly addresses manic pathophysiology. This is effectively a validated known indication rather than a novel repurposing discovery, which serves as a positive control for the TxGNN model’s predictive capability. However, the drug is currently not registered in the Philippines, presenting a potential market access opportunity.

The top 9 TxGNN predictions (ranks 1–9) are all recommended as Hold due to:

All are ultra-rare congenital/genetic disorders with no clinical evidence (L5)
No mechanistic rationale for D2 antagonism in these conditions
Several predictions may be contraindicated (myopia variants, CMT1G)

To proceed, the following is needed:

Regulatory pathway assessment for haloperidol registration in the Philippines
Detailed MOA data from DrugBank to support formal documentation
Philippine-specific package insert with local warnings and contraindications
Drug-drug interaction database query to populate DDI safety profile
Comparative cost-effectiveness analysis against atypical antipsychotics (risperidone, olanzapine) already available in the Philippines for bipolar mania
EPS monitoring protocol given haloperidol’s higher EPS burden compared to atypical alternatives

This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Data cutoff: 2026-04-05 | Evidence Pack version: v4 | Candidate ID: TW-DB00502-multi

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.